Precision BioSciences Inc logo

DTIL - Precision BioSciences Inc Share Price

$6.18 -0.0  -0.2%

Last Trade - 9:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £255.4m
Enterprise Value £110.2m
Revenue £17.9m
Position in Universe 2999th / 6323
Bullish
Bearish
Unlock DTIL Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

DTIL Revenue Unlock DTIL Revenue

Net Income

DTIL Net Income Unlock DTIL Revenue

Normalised EPS

DTIL Normalised EPS Unlock DTIL Revenue

PE Ratio Range

DTIL PE Ratio Range Unlock DTIL Revenue

Dividend Yield Range

DTIL Dividend Yield Range Unlock DTIL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DTIL EPS Forecasts Unlock DTIL Revenue
Profile Summary

Precision BioSciences, Inc. is a genome editing company. The Company is engaged in providing genome engineering technology. The Company’s ARCUS genome editing technology enables the production of specific nucleases that can insert, remove and modify deoxyribonucleic acid (DNA) at any location in a genome. The Company is also engaged in developing genome editing-based product leads for human therapeutic, agricultural and biologics manufacturing applications. The Company’s four product candidates in its CAR T cell development pipeline are PBCAR0191, PBCAR20A, PBCAR269A and PBCAR371A. The Company’s ARCUS platform designed to treat human diseases and create healthy and sustainable food and agricultural solutions. It also developing product candidates in three areas to overcome the limitations of other genome editing technologies: allogeneic CAR T immunotherapy, in vivo gene correction, and food.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated January 26, 2006
Public Since March 28, 2019
No. of Shareholders: 221
No. of Employees: 199
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 51,399,847
Free Float (0.0%)
Eligible for
ISAs
SIPPs
DTIL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DTIL
Upcoming Events for DTIL
Similar to DTIL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.